Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Cell Death and Disease (2014) 5, e1149; doi:10.1038/cddis.2014.115
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2015
- Creator
-
Diessner, J.
Bruttel, V.
Stein, R. G.
Horn, E.
Häusler, S. F. M.
Dietl, J.
Hönig, A.
Wischhusen, J.
- URN
-
urn:nbn:de:bvb:20-opus-119884
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Diessner, J.
- Bruttel, V.
- Stein, R. G.
- Horn, E.
- Häusler, S. F. M.
- Dietl, J.
- Hönig, A.
- Wischhusen, J.
- Universität Würzburg
Time of origin
- 2015
Other Objects (12)
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor